WSTAM
CORT icon

Wilbanks Smith & Thomas Asset Management’s Corcept Therapeutics CORT Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100
Closed -$1K – 538
2018
Q3 		$1K Buy
+100
New +$1.4K ﹤0.01% 1502

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's CORT Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Corcept Therapeutics (CORT) in Q4 2018, closing a stake of 100 shares — an estimated $1K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in CORT in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 222 funds tracked by Wall St. Rank hold CORT as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Corcept Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 100 Corcept Therapeutics shares in Q4 2018, an estimated $1K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Corcept Therapeutics in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Corcept Therapeutics position peaked at $1K in Q3 2018.
  • 222 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.